Related by context. All words. (Click for frequent words.) 82 cytogenetic response 81 complete cytogenetic response 80 CCyR 79 response CCyR 75 cytogenetic responses 75 MCyR 72 pCR 72 patients evaluable 71 chlorambucil 71 HBeAg positive patients 71 CR nPR 70 CR CRu 70 complete remissions 70 ACR# response 70 achieved CCyR 69 undetectable HBV DNA 69 sustained virologic response 69 remission CR 69 evaluable patients 69 imatinib 69 undetectable HCV RNA 69 HBeAg seroconversion 69 nilotinib 69 achieved PASI 69 achieved sustained virologic 69 evaluable subjects 68 ACR Pedi 68 partial remissions 68 dasatinib 68 Solid Tumors criteria 68 biochemical relapse 68 log# reduction 68 Response Evaluation Criteria 68 achieved ACR# 68 achieved sustained virological 68 splenectomized patients 67 HBeAg 67 tumor shrinkage 67 ACR# responses 67 CIMZIA TM 67 CRp 67 clinically meaningful improvement 67 mg kg dose 67 DAS# remission 67 SVR# 67 RECIST criteria 66 sustained virological response 66 RECIST Response Evaluation Criteria 66 sUA 66 PSA nadir 66 Ph + 66 plus dexamethasone 66 PASI scores 66 imatinib therapy 66 virologic response 66 HBeAg negative patients 66 lymphocytosis 66 annualized relapse 66 bortezomib refractory 66 seroprotection 66 Scale EDSS 65 evaluable 65 HUMIRA achieved PASI 65 platelet reactivity 65 placebo dexamethasone 65 ribavirin RBV 65 endoscopic remission 65 Crohn Disease Activity 65 #mg dose [002] 65 NNRTI resistance 65 nodular partial response 65 oblimersen 65 HBV DNA 65 Rate ORR 65 receiving golimumab 65 Flu Cy 65 virologic failure 65 heavily pretreated 65 alanine aminotransferase ALT 65 clodronate 65 detectable HCV RNA 65 REYATAZ r arm 64 undetectable viral load 64 EGFR TKI 64 progression TTP 64 mg ustekinumab 64 pegylated interferon alpha 64 PSADT 64 follicular lymphomas 64 tumor regression 64 docetaxel chemotherapy 64 LEXIVA r 64 tumor recurrence 64 FOLFOX4 64 microbiological eradication 64 virological response 64 plus methotrexate 64 cEVR 64 glycated hemoglobin levels 64 HBV DNA levels 64 Doxil ® 64 adefovir 64 definite stent thrombosis 64 RGT arm 63 ACTEMRA TM 63 abnormal p# biomarker 63 serum urate 63 ACR# [002] 63 certolizumab 63 Fludara 63 T#I [002] 63 lopinavir r arm 63 prior relapsers 63 HCV RNA 63 8mg/kg 63 postdose 63 relapsed MM 63 virological failure 63 mycophenolate mofetil 63 chemoradiotherapy 63 Psoriasis Area 63 octreotide LAR 63 HER2 expression 63 antibody titers 63 postoperative chemotherapy 63 #mg BID [001] 63 ALND 63 prospectively defined 63 PEG IFN 63 peginterferon 63 neoadjuvant chemotherapy 63 interferon beta therapy 63 ertapenem 63 mg/m2 dose 63 imipenem 63 decitabine 63 mucosal healing 63 metastatic CRC 63 CIMZIA ™ 63 Solid Tumors RECIST 63 Median survival 63 mcg BID 63 neoadjuvant 63 seropositive patients 63 log# IU mL 63 adalimumab 63 log# 63 Free Survival PFS 63 locoregional recurrence 62 achieving PASI 62 virologic suppression 62 RECIST 62 FOLPI 62 peg interferon 62 azacytidine 62 receiving VICTRELIS 62 binary restenosis 62 prior chemotherapy regimens 62 azacitidine 62 tipranavir ritonavir 62 TMC# r 62 CLL SLL 62 Complete Response CR 62 locoregional disease 62 recurrent GBM 62 bendamustine 62 Aptivus ® 62 mRCC 62 baseline HbA1c 62 FluCAM 62 aminotransferase elevations greater 62 underwent resection 62 morphometric vertebral fractures 62 % Confidence Interval 62 imatinib Gleevec 62 serum HBV DNA 62 virologic 62 alfa 2a 62 elevated ALT 62 T#I mutation 62 viral kinetics 62 log# copies mL 62 chemoradiation 62 HDRS 62 neostigmine 62 response pCR 62 MabCampath 62 thyroglobulin 62 radiographic progression 62 plasma uric acid 62 Index CDAI 62 comparator arm 62 mg QD 62 undetectable virus HCV 62 PegIFN RBV 62 antibody titer 62 metastatic GIST 62 BARACLUDE ® 62 median PFS 62 HSCT 62 dose cohort 62 undetectable viral 62 iPTH 62 piperacillin tazobactam 62 TNF antagonist 62 nonresponders 62 peginterferon alfa 2a #KD 62 plus ribavirin 62 daunorubicin 62 cytoreduction 62 Expanded Disability Status 62 histologically confirmed 62 recurrent glioblastoma multiforme 62 CHOP chemotherapy 62 lumbar spine BMD 62 Ishak fibrosis score 62 oxycodone CR 62 leukemia ALL 62 pegylated liposomal doxorubicin 62 confirmed CCyR 62 dosing cohort 61 oral allopurinol 61 Peg IFN 61 mg BID dose 61 CIN2 + 61 IFN α 61 nab paclitaxel 61 Partial Response 61 Dasatinib 61 doripenem 61 Virologic 61 CDAI score 61 plasma HCV RNA 61 distant metastases 61 secondary efficacy endpoint 61 rapid virologic response 61 cabazitaxel 61 liver histology 61 leukemia AML 61 systemic ALCL 61 HIV RNA 61 EDSS score 61 lung metastases 61 standard chemotherapy regimen 61 fosamprenavir 61 ACR# ACR# 61 PREZISTA r arm 61 adjunctive placebo 61 haematologic 61 pegylated interferon alfa 61 MACCE 61 graft dysfunction 61 Telbivudine 61 K ras mutations 61 mcg albinterferon alfa 2b 61 secondary endpoint 61 mcg dose 61 mesalamine granules 61 desvenlafaxine succinate 61 % CI #.#-#.# [003] 61 estramustine 61 dalteparin 61 DAS# CRP 61 graft occlusion 61 serum HCV RNA 61 pancreatic adenocarcinoma 61 placebo p = 61 QTcF 61 neurologic progression 61 interferon alfa 2b 61 hematologic toxicity 61 paraprotein 61 KRAS mutations occur 61 tumor necrosis 61 tocilizumab 61 5-FU/LV 61 copies mL 61 Kaplan Meier analysis 61 achieve sustained virologic 61 liver metastases 61 DMARD 61 CANCIDAS 61 alteplase 61 mutated KRAS 61 odanacatib 61 Hycamtin ® 61 NLX P# 61 preoperative chemotherapy 61 serologically active patients 61 mcg mL 61 metastatic malignant 61 secondary efficacy endpoints 61 paricalcitol 61 metastatic lesions 61 abacavir lamivudine 61 tumor regressions 61 underwent surgical resection 61 dosing cohorts 61 Secondary endpoints include 61 caspofungin 61 mg BID 61 AZT zidovudine Retrovir 61 follicular NHL 61 5 Fluorouracil 61 Hb A1C 61 μg dose 61 dose cohorts 61 CDAI 61 dose dexamethasone 60 free survival PFS 60 serum phosphate 60 4mg/kg 60 dexamethasone Decadron 60 Engerix B 60 pT2 60 hemoglobin A1c levels 60 ALT flares 60 Gleevec resistant 60 NIHSS 60 tolvaptan 60 degarelix 60 -#.# log# copies mL 60 viral suppression 60 EDSS scores 60 infliximab 60 mg/m2/day 60 plus MTX 60 cinacalcet 60 corticosteroid dose 60 CMV disease 60 topotecan 60 neoadjuvant therapy 60 cytogenic 60 nadolol 60 XIENCE V PROMUS Stent 60 breast carcinomas 60 ponatinib 60 rhTSH 60 rosuvastatin #mg 60 peginterferon alfa 2a 60 Median progression 60 molecular remissions 60 platinum refractory 60 relapsers 60 SCIg 60 nicardipine 60 #mg QD [002] 60 Lupuzor ™ 60 amoxicillin clavulanate 60 flutamide 60 chemoradiation therapy 60 peginterferon alfa 2b 60 gefitinib 60 dose clopidogrel 60 papillary renal cell carcinoma 60 Pegasys ® 60 mcg Albuferon 60 APTIVUS r 60 experienced virologic failure 60 DAS# [002] 60 trastuzumab Herceptin ® 60 seroconversion 60 tipranavir 60 irbesartan 60 HbA1c levels 60 serum urate levels 60 A1c levels 60 leukemia CLL 60 noninferior 60 mcg kg 60 operable breast cancer 60 receiving INTRON 60 advanced adenoma 60 serum uric acid 60 Median PFS 60 goserelin 60 clinically evaluable patients 60 biochemical recurrence 60 ritonavir boosted 60 Tumor shrinkage 60 galiximab 60 nondiabetic patients 60 interferon ribavirin 60 aspartate aminotransferase AST 60 gastrointestinal stromal tumors 60 median survivals 60 heavily pretreated patients 60 anthracycline taxane 60 docetaxel Taxotere 60 baseline LDH 60 cervical intraepithelial neoplasia 60 carboplatin paclitaxel 60 mcg QD 60 tPSA 60 HbA1C 60 tamoxifen therapy 60 specific antigen PSA 60 genotypic resistance 60 EXJADE 60 advanced adenomas 60 lumiliximab 60 timepoint 60 Omacetaxine 60 durable remissions 60 dasatinib Sprycel 60 idarubicin 60 tipranavir r 60 null responders 60 GnRH agonist 60 FOLFOX 60 -#.# log# 60 metastatic RCC 60 ULORIC 60 dacarbazine 60 eosinophilic asthma 60 IU ml 60 clinically meaningful improvements 60 NMIBC 60 raltegravir 60 rituximab 60 lamivudine monotherapy 60 HER2 overexpression 60 #.#ng/ml 60 everolimus eluting stents 60 alicaforsen enema 60 Thal Dex 60 mg dose 60 fluvastatin 60 Nilotinib 60 serum clusterin levels 60 PEG interferon 60 #mg/day [002] 59 DAPT 59 zoledronic acid 59 acute GvHD 59 doxorubicin cyclophosphamide 59 radiochemotherapy 59 HCV infected 59 oral rivaroxaban 59 adalimumab Humira 59 eosinophil count 59 colorectal liver metastases 59 gastrointestinal stromal tumor GIST 59 Solid Tumors 59 mg TID 59 isoproterenol 59 hepatitis C genotype 59 serum testosterone 59 leukemia CML 59 debulking surgery 59 #mg dose [001] 59 taxane chemotherapy 59 adjuvant tamoxifen 59 pediatric acute lymphoblastic 59 methotrexate monotherapy 59 dose melphalan 59 mCi kg 59 entecavir 59 Folfox 59 posttreatment 59 vWF 59 posaconazole 59 renal cell carcinomas 59 lymphocyte count 59 titrated glipizide 59 adriamycin 59 BENICAR HCT 59 metastatic lung cancer 59 alanine aminotransferase 59 Secondary endpoints 59 FOLFIRI 59 HBeAg positive 59 lymphopenia 59 HLA DR4 immune 59 low dose cytarabine 59 briakinumab 59 intact parathyroid hormone 59 Events MACE 59 EBRT 59 Sustained virologic response 59 μmol L 59 MGd 59 aspartate aminotransferase 59 CRu 59 Fludara ® 59 Partial Responses 59 adenoma recurrence 59 EGFR mutations 59 severe neutropenia 59 pT3 59 Secondary endpoints included 59 Index CDAI score 59 LHRH analogues 59 APTIVUS R 59 distant metastasis 59 virological suppression 59 fulvestrant 59 remission induction 59 interferon beta 59 FOLFOX6 59 gemcitabine carboplatin 59 infusional 5-FU/LV 59 mg qd 59 neutrophil count 59 paclitaxel cisplatin 59 asymptomatic carotid stenosis 59 ribavirin therapy 59 #.#/#.# mmHg [001] 59 lamivudine 59 virologic responses 59 ZOLINZA 59 ximelagatran 59 serum cortisol 59 somatostatin analog 59 pegfilgrastim 59 R0 resection 59 octreotide 59 XIENCE V demonstrated 59 plus prednisone 59 FOLFOX4 alone 59 β blockers 59 Campath alemtuzumab 59 serum phosphorus 59 pegylated interferon alfa 2a 59 eplerenone 59 HLA DR2 59 relapsed AML 59 NPH insulin 59 5-fluorouracil/leucovorin 59 metastatic renal cell carcinoma 59 FOLFIRINOX 59 HBsAg 59 pmol L 59 teriflunomide 59 NRTIs 59 ARB telmisartan 59 hours postdose 59 ALT elevation 59 trans retinoic acid ATRA 59 hypereosinophilic syndrome 59 SCr 59 anti HBs 59 ALT normalization 59 colorectal carcinoma 59 refractory NSCLC 59 TEAEs 59 KRAS wild 59 TACE 59 nutlin 3a 59 DFMO 59 Primary endpoints 59 previously untreated follicular 59 Amrubicin 59 COPAXONE R 59 neoadjuvant treatment 59 Gefitinib 59 ABC/3TC 59 peginterferon alpha 2a 59 hemagglutination inhibition 59 gemcitabine Gemzar 59 OGTT 59 lactate dehydrogenase LDH 59 sunitinib 59 etanercept 59 oral FTY# 59 hematologic 59 Recurrence Score 59 GSTP1 59 biliary tract cancer 59 HPV-#/# 59 SUVmax 59 lispro 59 sunitinib Sutent 59 mg m² 59 alkylating agent 59 MAGE A3 ASCI 59 LPV r 59 tolterodine ER 59 troponin T 59 TTR gene 59 elotuzumab 59 Decitabine 59 low expressors 59 CYPHER Stent 58 INCB# [003] 58 unresectable tumors 58 prespecified 58 % CI #.#-#.# [007] 58 recurrent VTE 58 BRAF mutations 58 serum concentrations 58 EBMT criteria 58 lamivudine refractory patients 58 CsA 58 TNFalpha 58 #Gy 58 Target Lesion Revascularization TLR 58 Follicular Lymphoma 58 refractory AML 58 corticosteroid therapy 58 preoperative PSA 58 serum prostate 58 ibandronate 58 fasting plasma glucose FPG 58 bicalutamide 58 chemo radiotherapy 58 CIN3 58 MADRS score 58 surrogate endpoint 58 Irinotecan 58 statistically significant efficacy 58 sorafenib Nexavar 58 Jevtana 58 ACZ# 58 tapentadol ER 58 adjuvant radiation 58 follicular lymphoma 58 rimonabant #mg 58 chronic myeloid leukemia CML 58 steroid dexamethasone 58 familial ALS 58 invasive ductal 58 daily subcutaneous injections 58 TroVax ® 58 events MACE 58 Sustained Virological Response 58 adjunctive ABILIFY 58 insulin detemir 58 Zevalin R Ibritumomab 58 bevacizumab Avastin ® 58 hypogonadal men 58 PEG Intron 58 Durezol 58 crizotinib PF # 58 pyrazinamide 58 IFN beta 58 mcg kg REBETOL 58 VELCADE melphalan 58 leukocyte count 58 resected pancreatic cancer 58 transaminases 58 lymphocyte counts 58 p = NS 58 anemia hemoglobin 58 plus gemcitabine 58 peripheral blood mononuclear 58 thyroid carcinoma 58 TOP2A 58 TIMP 1 58 febrile neutropenia 58 Hazard Ratio 58 aminotransferase ALT 58 rituximab monotherapy 58 placebo p 58 fluticasone salmeterol 58 reinfarction 58 CTAP# Capsules 58 uM 58 Pegasys plus Copegus 58 antibody responses 58 blood phenylalanine Phe 58 peginterferon alfa 58 oral diclofenac 58 relapsed MCL 58 CIMZIA TM certolizumab pegol 58 mitoxantrone chemotherapy 58 huN# DM1 58 mCRC patients 58 postintervention 58 pertuzumab 58 TAXUS p value 58 gefitinib Iressa 58 epithelial tumors 58 gout flares 58 blastic phase 58 BENICAR 58 transaminase elevations 58 Combination therapy 58 VFEND 58 FLT3 ITD 58 grade cervical intraepithelial 58 microg 58 radioiodine therapy 58 visceral metastases 58 severe oral mucositis 58 nanomolar 58 OADs 58 Xanafide 58 DMARDs 58 glycosylated hemoglobin HbA1c 58 relapsed refractory 58 perioperative complications 58 thalidomide Thalomid 58 cisplatin resistant 58 mg RDEA# 58 stage IIIb IV 58 Natalizumab 58 cranial irradiation 58 moderate renal impairment 58 HGS ETR1 58 intradermal injection 58 serum calcium levels 58 concurrent chemoradiation 58 FIRMAGON 58 NAbs 58 canakinumab 58 imatinib resistant 58 Fludarabine 58 Bezielle 58 indolent NHL 58 Cytoxan 58 fallopian tube cancers 58 Clusterin 58 Scale EDSS score 58 radical prostatectomy RP 58 severe exacerbations 58 sipuleucel T 58 gemcitabine cisplatin 58 lopinavir r 58 aminotransferase levels 58 fluoropyrimidine 58 TREANDA 58 dose cytarabine 58 rindopepimut 58 cardiovascular calcification 58 angiographic outcomes 58 cisplatin gemcitabine 58 ALT elevations 58 Kaplan Meier estimate 58 imatinib mesylate Gleevec 58 HCV RESPOND 2 58 BRAF mutation 58 imatinib resistance 58 splenectomized 58 HGPIN 58 mm Stent 58 anastrozole 58 serum creatinine levels 58 VIDAZA 58 composite endpoint 58 prostate adenocarcinoma 58 adefovir treated 58 metastatic malignant melanoma 58 sarcomatoid 58 infliximab therapy 58 serum ALT 58 rFVIIa 58 hyperphenylalaninemia HPA due 58 tirofiban 58 lopinavir 58 FluCAM arm 58 Pemetrexed 58 pegylated alpha interferon 58 HbA 1c 58 PROMACTA 58 SSc 58 serum thyroglobulin 58 peg IFN 58 PRADAXA #mg 58 Raptiva r 58 docetaxel 58 atazanavir ritonavir 58 antihypertensive therapy 58 Pharmacokinetic parameters 58 serum phosphate levels 57 histologic subtypes 57 TPV r 57 protease inhibitor PI 57 standard chemotherapy regimens 57 inflammatory lesions 57 interferon IFN 57 cisplatin chemotherapy 57 paroxysmal AF 57 YERVOY 57 serum antibody 57 baseline FEV 57 endocrine therapy 57 PEGylated anti 57 paclitaxel eluting stents 57 methotrexate therapy 57 myocardial necrosis 57 oral clodronate 57 urinary N telopeptide 57 Platinol ® 57 HCV replicon 57 undetectable PSA 57 CML CP 57 prospectively stratified 57 lenalidomide Revlimid R 57 doxorubicin docetaxel 57 q#d 57 immunostaining 57 adjuvant hormonal therapy 57 Severity Index PASI 57 5FU 57 mL/min/#.# m 2 57 exemestane 57 Bortezomib 57 statistically significant p = 57 receiving APTIVUS r 57 interferon alfa 57 telbivudine 57 platelet inhibition 57 idraparinux 57 metastatic renal cell 57 R# #mg BID 57 HCV genotype 57 androgen ablation 57 calcineurin inhibitor 57 baseline PASI 57 telaprevir dosed 57 seropositivity 57 gastrointestinal stromal tumors GIST 57 neutralizing antibody 57 macroalbuminuria 57 mg kg cohorts 57 Trastuzumab 57 bFGF 57 iniparib 57 demonstrated antitumor activity 57 darunavir ritonavir 57 dacarbazine DTIC 57 ug kg 57 superficial bladder cancer 57 androgen deprivation 57 Imatinib 57 Ki# 57 ancrod 57 HAQ DI 57 basiliximab 57 mitoxantrone plus 57 virologic response EVR 57 XELOX 57 rFSH 57 IOP lowering 57 Ph + ALL 57 dasatinib Sprycel ® 57 taxane therapy 57 sinus rhythm 57 biologic therapy 57 tenecteplase 57 receiving highly emetogenic 57 FUSILEV enhances 57 lanreotide 57 TTF Therapy 57 cytoreductive surgery 57 infarct size 57 neutrophil counts 57 timepoints 57 edifoligide 57 evaluating tivozanib 57 Vidaza ® 57 prednisone prednisolone 57 lung metastasis 57 lymph node metastasis 57 bcr abl 57 precancerous cervical lesions 57 q#h 57 concomitant antibiotics 57 DOXIL 57 biologic DMARD 57 antithymocyte globulin 57 weekly intravenous infusions 57 DLTs 57 chronic eosinophilic leukemia 57 Neoadjuvant 57 VIRAMUNE 57 refractory CML 57 systemic corticosteroid 57 recovery CRp 57 LVEF 57 antiangiogenic therapy 57 alpha 2a 57 hemoglobin A1c HbA1c 57 Etanercept 57 oral vancomycin 57 apolipoprotein B 57 huC# DM4 57 IL#B 57 detemir 57 TAXUS Express Stent 57 HER2/neu 57 HbA1c 57 receiving prophylactic anticoagulation 57 cell lymphoma CTCL 57 Vidaza azacitidine 57 GHRH 57 PEGylated Fab fragment 57 K#N 57 #q# deletion syndrome 57 rapid virological response 57 NNRTIs 57 Cytogenetic 57 VGPR 57 colesevelam HCl 57 ng dL 57 Castration Resistant Prostate Cancer 57 glioblastomas 57 Kantarjian 57 Montgomery Åsberg Depression 57 tumor histology 57 rimonabant #mg/day 57 CDI recurrence 57 Pred Forte 57 alefacept 57 IFN alfa 57 FOLPI regimen 57 ATACAND 57 chronic angina 57 thrombocytopenic 57 REYATAZ r 57 angiographic restenosis 57 GBM tumors 57 adjuvant radiotherapy 57 anagrelide 57 ErbB2 positive 57 virologic breakthrough 57 SELENA SLEDAI score 57 prostate carcinoma 57 pomalidomide 57 Operative mortality 57 cTnI 57 hsCRP levels 57 clinically meaningful 57 parathyroidectomy 57 μg doses 57 noninferiority 57 SLNB 57 amprenavir 57 nitazoxanide 57 ipsilateral stroke 57 Sprycel dasatinib 57 KRAS mutant tumors 57 rizatriptan 57 talabostat 57 disease modifying antirheumatic 57 tumor resection 57 cells uL 57 IFN alpha 57 icatibant 57 TLUS 57 HER2 positive tumors 57 imiquimod 57 HOMA IR 57 CVP chemotherapy 57 undergone splenectomy 57 dexpramipexole 57 microgram kg 57 baminercept 57 Rating Scale MADRS 57 fluorouracil leucovorin 57 dacarbazine chemotherapy 57 erlotinib Tarceva 57 pegylated interferon peg IFN 57 achieved statistical significance 57 seroprotective 57 docetaxel Taxotere ® 57 BEXXAR 57 cytologically confirmed 57 HER2 positive metastatic breast 57 Chronic Myeloid Leukemia 57 carvedilol 57 pain palliation 57 achieving sustained virologic 57 pegylated liposomal doxorubicin PLD 57 lymphoid malignancies 57 sUA levels 57 lactate dehydrogenase 57 hepatitis B immunoglobulin 57 indinavir 57 IFN gamma 57 postprocedure 57 limiting toxicity 57 chronic GVHD 57 PEGINTRON TM 57 cystectomy 57 primary patency 57 ruboxistaurin 57 TAXUS Stent 57 #mg BID [003] 57 efficacy endpoint 57 subtrochanteric 57 dapagliflozin plus 57 colorectal adenoma 57 taxane refractory 57 Camptosar ® 57 EUFLEXXA R 57 vandetanib 57 serum IGF 57 #mg/day [001] 57 glargine 57 tumor lysis syndrome 57 dosage regimens 57 NYHA functional class 57 RoACTEMRA 57 metastatic kidney 57 Non inferiority 57 F FDG PET 57 boosted protease inhibitor